2027 ICD-10-CM Diagnosis Code E71.0Maple-syrup-urine disease

ICD-10-CM Codes›E00–E89›E70-E88›E71

ICD-10-CM E71.0
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

E71.0 is a billable ICD-10-CM diagnosis code for maple-syrup-urine disease. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 642. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 140 closely related codes. Coders also document this condition as classical maple syrup urine disease. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

E71.0 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2027.

Code Identity

ICD-10-CM Code
E71.0
Billable Status
Yes — Valid for Submission
Code Describes
Maple-syrup-urine disease
Short Description
Maple-syrup-urine disease
Same as the full description in the CMS dataset.
Parent Code
Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE71Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism
This CodeE71.0Maple-syrup-urine disease

Medicare Risk Adjustment (HCC)Billing

E71.0 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.

CMS-HCC V28 (Medicare Advantage Payment Model)
Not mapped
Dropped in V28 see all codes that no longer risk-adjust
Prior Model (CMS-HCC V24)
HCC 23
V24 retired last contributed to a Medicare Advantage risk score in payment year 2025
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
RxHCC 43 — Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Classical maple syrup urine disease
  • Dihydrolipoamide dehydrogenase deficiency
  • Intermediate maple syrup urine disease
  • Intermittent maple syrup urine disease
  • Maple syrup urine disease
  • Maple syrup urine disease, multiple dehydrogenase form
  • Mild maple syrup urine disease
  • Thiamin-responsive maple syrup urine disease

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to E71.0: its own notes plus those printed at block E70-E88 and Chapter 4. A note printed at a category, block or chapter applies to every code under it.

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From Block E70-E88 Metabolic disorders applies to 286 codes
  • androgen insensitivity syndrome (E34.5-)
  • congenital adrenal hyperplasia (E25.0)
  • hemolytic anemias attributable to enzyme disorders (D55.-)
  • Marfan syndrome (Q87.4-)
  • 5-alpha-reductase deficiency (E29.1)
From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block E70-E88 Metabolic disorders applies to 286 codes
  • Ehlers-Danlos syndromes (Q79.6-)

Notes

General instructions on how these codes are used.

From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name E71.0, its category, or a range that includes it.

Excludes1 4

These codes carry an Excludes1 note naming E71.0: they are not reported together with it, unless the two conditions are unrelated.

  • E72 Other disorders of amino-acid metabolism
    branched-chain amino-acid metabolism (E71.0-E71.2)
  • R79 Other abnormal findings of blood chemistry
    specific findings indicating disorder of amino-acid metabolism (E70-E72) names E70-E72, which includes this code
  • R79.83 Abnormal findings of blood amino-acid level
    disorders of amino-acid metabolism (E70-E72) names E70-E72, which includes this code
  • Block R80-R82 Abnormal findings on examination of urine, without diagnosis
    specific findings indicating disorder of amino-acid metabolism (E70-E72) names E70-E72, which includes this code

Index to Diseases and InjuriesGuidance

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Maple Syrup Urine Disease

    an autosomal recessive inherited disorder with multiple forms of phenotypic expression, caused by a defect in the oxidative decarboxylation of branched-chain amino acids (amino acids, branched-chain). these metabolites accumulate in body fluids and render a maple syrup odor. the disease is divided into classic, intermediate, intermittent, and thiamine responsive subtypes. the classic form presents in the first week of life with ketoacidosis, hypoglycemia, emesis, neonatal seizures, and hypertonia. the intermediate and intermittent forms present in childhood or later with acute episodes of ataxia and vomiting. (from adams et al., principles of neurology, 6th ed, p936)

Patient EducationClinical

Metabolic Disorders

Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system break the food parts down into sugars and acids, your body's fuel.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E71.0 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
270.3 Bran-chain amin-acid dis
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About E71.0Overview

What is the ICD-10 code for maple-syrup-urine disease?

The ICD-10-CM code for maple-syrup-urine disease is E71.0 (sometimes written as E710). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is E71.0 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report maple-syrup-urine disease on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does E71.0 group to?

When maple-syrup-urine disease is the principal diagnosis on an inpatient stay, it groups to MS-DRG 642 (inborn and Other Disorders of Metabolism), which carries a relative weight of 1.3226. Higher weights mean higher Medicare reimbursement.

Is E71.0 a CC or MCC?

CMS lists E71.0 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 140 closely related codes in its exclusion list.

Can E71.0 be reported with a code from E34.5?

Not as a rule. The Excludes1 note at block E70-E88, which applies to E71.0, lists "androgen insensitivity syndrome (E34.5-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

Does E71.0 risk-adjust for Medicare Advantage payment?

Not for Medicare Advantage. E71.0 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).